Cancer Genetics to Report Second Quarter 2018 Financial Results on August 14, 2018
Published on: Tuesday, August 7th, 2018 View all Media
Conference call at 8:30 a.m. EDT, Tuesday, August 14, 2018
RUTHERFORD, N.J., Aug. 07, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that it will release its financial results for the second quarter ended June 30, 2018 on Tuesday, August 14, 2018 during pre-market hours. The Company will hold a conference call at 8:30 a.m. Eastern on Tuesday, August 14, 2018 to discuss the financial results and provide an update on its strategic direction and key organizational improvements being made by the Company.
|CONFERENCE CALL & WEBCAST|
|Tuesday, August 14, 2018, 8:30 a.m. Eastern Time|
|Replay – Available through August 28, 2018|
ABOUT CANCER GENETICS
Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, Australia and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.